Incannex Healthcare Regains Nasdaq Compliance After 11-Day $1 Bid, Holds $75M Cash
Incannex Healthcare regained compliance with Nasdaq’s minimum bid price rule after its stock closed at $1.00 or above for 11 consecutive business days through March 13, 2026. The company holds about $75 million in cash with no debt and is advancing Phase 2 programs IHL-42X and PSX-001.
1. Nasdaq Compliance Restoration
Incannex Healthcare received written confirmation that its common stock met the $1.00 minimum bid price for 11 consecutive business days from February 27 to March 13, 2026, satisfying Nasdaq Listing Rule 5550(a)(2) and securing its continued listing on the Nasdaq Capital Market.
2. Financial Position and Listing Security
The company reports approximately $75 million in cash with no outstanding debt, removing a technical overhang on its shares and reinforcing its ability to fund operations and clinical programs without immediate financing concerns.
3. Clinical Pipeline Advances
Incannex is advancing its lead candidate IHL-42X, which achieved statistically significant Phase 2 results for obstructive sleep apnea, and PSX-001, which has shown positive outcomes in generalized anxiety disorder, with both programs approaching key development milestones.